|
Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1 Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1 conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1 Clinical research trials and Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1 healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1. Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1 Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1 clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1 condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1  Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1
Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1
For Condition: Substance-Related Disorders,Infusions, Intravenous,Substance Abuse, Intravenous
Status: No longer recruiting
Sponsor(s): National Institute on Drug Abuse (NIDA) ,
Synopsis: An assessment of potential interactions between intravenous methamphetamine and oral selegiline.
Details: To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Single Blind, Placebo Control
Minimum Age/Maximum Age: 18 Years/45 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals; between 18-45 yrs of age; be able to verbalize understanding of consent form; provide written informed consent Exclusion Criteria: Additional criteria available during screening at the site
Total Enrollment: 16
Location and Contact Information:
Overall Study Official:
ThomasNewton, Principal Investigator, University of California, Los Angeles
UCLA Integrated Substance Abuse Program
Los Angeles, California, 90024
United States
Additional Information:
Study ID Numbers: NIDA-CTO-0004-1;
Study Start Date: September 2001
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00033072
Other Substance-Related Disorders Studies:
1. Counseling Conditions for Thrice Weekly Buprenorphine in a Primary Care Clinic - 1
2. Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1
Related Studies:
Other Substance-Related Disorders Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline - 1
|
|
|
|
|
|
|
|
